Myeloid mutations in ALL and their role in identifying those at risk of secondary malignancies
Ilaria Iacobucci, PhD, St. Jude Children’s Research Hospital, Memphis, TN, comments on the presence of myeloid mutations in acute lymphoblastic leukemia (ALL). She highlights that these mutations can occur in stem cells and promote a pre-leukemic expansion, often involving genes such as IDH2, DNMT3A, and RUNX1. These mutations are crucial for identifying patients at risk of secondary malignancies, including myeloid malignancies, and can be found not only in leukemic blasts but also in normal cells. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
